Search research articles
Contact Us
Filters
Showing results (111-120 of 118) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 118 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian Cancer
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Lancet (London, England)
|
February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting
Jennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2021
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
Melanie Royce, Christy L Osgood, Anup K Amatya, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 118) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 118 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian Cancer
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
Melanie Royce, Mirat Shah, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.
Lancet (London, England)
|
February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting
Jennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2021
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
Melanie Royce, Christy L Osgood, Anup K Amatya, et al.
Page
of 12